Taysha gene therapies announces publication of positive proof-of-concept preclinical data for an aav-mediated ube3a gene replacement approach demonstrating therapeutic potential for the treatment of angelman syndrome in the journal jci insight

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced the publication of new preclinical data for an aav-mediated ube3a gene replacement approach for the treatment of angelman syndrome in the journal of clinical investigation i
TSHA Ratings Summary
TSHA Quant Ranking